tiprankstipranks
Advertisement
Advertisement

SRPT Stock Latest News

Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13
RatingsSell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13
2d ago
SRPT
Citi sees intensifying competition for Sarepta from Dyne Therapeutics
PremiumThe Fly
Citi sees intensifying competition for Sarepta from Dyne Therapeutics
2d ago
DYN
SRPT
Tractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Tractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls
14d ago
AMT
CNK
Sarepta price target lowered to $20 from $23 at Piper Sandler
PremiumThe Fly
Sarepta price target lowered to $20 from $23 at Piper Sandler
14d ago
SRPT
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe Fly
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
15d ago
SRPT
H.C. Wainwright says Sarepta news does not signal full approvals
PremiumThe FlyH.C. Wainwright says Sarepta news does not signal full approvals
22d ago
SRPT
Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53
Premium
The Fly
Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53
23d ago
SRPT
Sarepta Shareholders Approve 2026 Equity and ESPP Plans
Premium
Company Announcements
Sarepta Shareholders Approve 2026 Equity and ESPP Plans
2M ago
8K
SRPT
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe Fly
Acting FDA head vows to block political interference, Endpoint News says
2M ago
AZN
BMY
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
PremiumCompany Announcements
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
2M ago
SRPT
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
2M ago
AZN
BMY
Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
PremiumRatings
Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
2M ago
SRPT
Sarepta price target lowered to $19 from $20 at Evercore ISI
PremiumThe FlySarepta price target lowered to $19 from $20 at Evercore ISI
2M ago
SRPT
FDA Commissioner Marty Makary resigns
Premium
The Fly
FDA Commissioner Marty Makary resigns
2M ago
AZN
BMY
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
Premium
The Fly
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
2M ago
AZN
BMY
Trump Trade: U.S. plans AI security order without required model tests
PremiumThe Fly
Trump Trade: U.S. plans AI security order without required model tests
2M ago
DYN
RNA
Trump approves plan to fire FDA head Marty Makary, CBS reports
PremiumThe Fly
Trump approves plan to fire FDA head Marty Makary, CBS reports
2M ago
DYN
RNA
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
PremiumRatings
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
2M ago
SRPT
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
PremiumRatings
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
3M ago
SRPT
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
PremiumRatingsGil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
3M ago
SRPT
Sarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
Premium
Ratings
Sarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
3M ago
SRPT
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
Premium
Ratings
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
3M ago
SRPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >